Literature DB >> 47656

Soluble proteins of bronchopulmonary secretions from patients with cystic fibrosis, asthma, and bronchitis.

T D Brogan, H C Ryley, L Neale, J Yassa.   

Abstract

The concentrations of nine plasma proteins were determined by quantitative immunoelectrophoresis in sputum specimens from 29 patients with cystic fibrosis (CF) and from 24 patients with severe asthma and chronic bronchitis. The results suggested that the population of CF patients could be divided into two groups in spite of an absence of difference in clinical status between the groups. Average concentrations of seven plasma proteins in sputum of group I CF patients were identical with those in sputum of patients with bronchitis, but the average concentrations of six of these proteins in sputum from group II CF patients were higher than those in specimens from the bronchitic patients and were similar to corresponding concentrations in sputum from patients with asthma, all of whom were examined while in status asthmaticus. The average concentrations of 14 secretory proteins were the same in all sputum specimens whether or not they were produced by patients with cystic fibrosis, asthma or bronchitis. It was concluded that the concentrations in the bronchopulmonary secretions of proteins associated with host defence were not diminished in patients with cystic fibrosis, and failure to produce adequate concentrations of proteins with antimicrobial activity was unlikely to be responsible for the above average susceptibility to chest infection in cystic fibrosis. It is suggested that there exists a group of CF patients in whom a pulmonary allergic reaction generates an inflammatory response as severe as that characterizing status asthmaticus and that this response could be detrimental.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 47656      PMCID: PMC470247          DOI: 10.1136/thx.30.1.72

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  10 in total

1.  EFFECT OF COMPLEMENT AND OF THE CARBOHYDRATE COMPONENTS OF SPUTUM ON PHAGOCYTOSIS BY HUMAN POLYMORPHONUCLEAR LEUCOCYTES.

Authors:  T D BROGAN
Journal:  Immunology       Date:  1964-11       Impact factor: 7.397

2.  MUCIN AS A RESISTANCE-LOWERING SUBSTANCE.

Authors:  L Olitzki
Journal:  Bacteriol Rev       Date:  1948-06

3.  Immunoglobulin production in bronchial mucosa and bronchial lymph nodes, particularly in cystic fibrosis of the pancreas.

Authors:  F J Martinez-Tello; D G Braun; W A Blanc
Journal:  J Immunol       Date:  1968-11       Impact factor: 5.422

4.  Bacterial precipitins in serum of patients with cystic fibrosis.

Authors:  M W Burns; J R May
Journal:  Lancet       Date:  1968-02-10       Impact factor: 79.321

5.  Studies of electroimmunodiffusion: immunochemical quantitation of proteins in dilute solutions.

Authors:  M Lopez; T Tsu; N E Hyslop
Journal:  Immunochemistry       Date:  1969-07

6.  A simplified cystic fibrosis scoring system (a preliminary report).

Authors:  E M Cooperman; M Park; J McKee; J P Assad
Journal:  Can Med Assoc J       Date:  1971-09-18       Impact factor: 8.262

7.  Variation in the composition of sputum in chronic chest diseases.

Authors:  H C Ryley; T D Brogan
Journal:  Br J Exp Pathol       Date:  1968-12

8.  Quantitative immunoelectrophoresis of human serum proteins.

Authors:  H G Clarke; T Freeman
Journal:  Clin Sci       Date:  1968-10       Impact factor: 6.124

9.  Abnormal serum factor in patients with cystic fibrosis of the pancreas.

Authors:  A Spock; H M Heick; H Cress; W S Logan
Journal:  Pediatr Res       Date:  1967-05       Impact factor: 3.756

10.  Multiple precipitins to cow's milk in chronic respiratory disease. A syndrome including poor growth, gastrointestinal symptoms, evidence of allergy, iron deficiency anemia, and pulmonary hemosiderosis.

Authors:  D C HEINER; J W SEARS; W T KNIKER
Journal:  Am J Dis Child       Date:  1962-05
  10 in total
  23 in total

Review 1.  Antimicrobial polypeptides in host defense of the respiratory tract.

Authors:  Tomas Ganz
Journal:  J Clin Invest       Date:  2002-03       Impact factor: 14.808

2.  Bronchorrhoea--separation of mucus and serum components in sol and gel phases.

Authors:  M T Lopez-Vidriero; I Das; L Reid
Journal:  Thorax       Date:  1979-08       Impact factor: 9.139

3.  Transmural calcium fluxes and role of mucins as cellular calcium-transport vehicles in chicken trachea in vitro.

Authors:  P W Kent; N Mian
Journal:  J Physiol       Date:  1987-07       Impact factor: 5.182

4.  A Moraxella catarrhalis two-component signal transduction system necessary for growth in liquid media affects production of two lysozyme inhibitors.

Authors:  Stephanie N Joslin; Christine Pybus; Maria Labandeira-Rey; Amanda S Evans; Ahmed S Attia; Chad A Brautigam; Eric J Hansen
Journal:  Infect Immun       Date:  2014-10-13       Impact factor: 3.441

5.  Effects and interactions of sensory neuropeptides on airway microvascular leakage in guinea-pigs.

Authors:  D F Rogers; M G Belvisi; B Aursudkij; T W Evans; P J Barnes
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

Review 6.  Adhesion molecules in a primate model of allergic asthma: clinical implications for respiratory care.

Authors:  R H Gundel; C D Wegner; L G Letts
Journal:  Springer Semin Immunopathol       Date:  1993

7.  Action of serum on the output of secretory glycoproteins from human bronchi in vitro.

Authors:  I P Williams; B Rich; P S Richardson
Journal:  Thorax       Date:  1983-09       Impact factor: 9.139

8.  Biochemical definition of human tracheobronchial mucus.

Authors:  P Roussel; P Degand; G Lamblin; A Laine; J J Lafitte
Journal:  Lung       Date:  1978       Impact factor: 2.584

9.  Aspects of serum and sputum antibody in chronic airways obstruction.

Authors:  C W Clarke
Journal:  Thorax       Date:  1976-12       Impact factor: 9.139

10.  Composition of bronchopulmonary secretions from patients with bronchiectasis.

Authors:  T D Brogan; B H Davies; H C Ryley; P J Ross; L Neale
Journal:  Thorax       Date:  1980-08       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.